Table 1.

Correlations between CENP-A pattern-C and non-C and patients and tumor characteristics.

Characteristic		Total (N = 62)	CENP-A Pattern
			C (N = 25)	Non-C (N = 37)	Test
Age (year)					NS
	Median (IQR)	62 (56–68)	61 (56–64)	63 (56–69)
Ki67 (%)					NS
	Median (IQR)	60 (35–75)	60 (35–75)	60 (30–75)
Gender N (%)					NS
	F	10 (16.1%)	6 (24%)	4 (10.8%)
	M	52 (83.9%)	19 (76%)	33 (89.2%)
T (TNM) N (%)					0.06
	T1	4 (6.5%)	1 (4%)	3 (8.1%)
	T2	10 (16.1%)	4 (16%)	6 (16.2%)
	T3	23 (37.1%)	14 (56%)	9 (24.3%)
	T4	25 (40.3%)	6 (24%)	19 (51.4%)
N (TNM) N (%)					NS
	N0	17 (27.4%)	8 (32%)	9 (24.3%)
	N1	7 (11.3%)	2 (8%)	5 (13.5%)
	N2a	3 (4.8%)	2 (8%)	1 (2.7%)
	N2b	9 (14.5%)	5 (20%)	4 (10.8%)
	N2c	19 (30.6%)	6 (24%)	13 (35.1%)
	N3	7 (11.3%)	2 (8%)	5 (13.5%)
Stage					NS
	I	1 (1.6%)	1 (4%)	0 (0%)
	II	3 (4.8%)	0 (0%)	3 (8.1%)
	III	18 (29%)	8 (32%)	10 (27%)
	IV	40 (64.5%)	16 (64%)	24 (64.9%)
Tumor Site N (%)					NS
	Oral cavity	5 (8.1%)	3 (12%)	2 (5.4%)
	Oropharynx	42 (67.7%)	17 (68%)	25 (67.6%)
	Hypopharynx	4 (6.5%)	0 (0%)	4 (10.8%)
	Larynx	11 (17.7%)	5 (20%)	6 (16.2%)
Metastatic Relapse N (%)					0.025
	No	49 (80.3%)	24 (96%)	25 (69.4%)
	Yes	12 (19.7%)	1 (4%)	11 (30.6%)
	NA	1	0	1
HPV N (%)					0.002
	HPV-	27 (43.5%)	5 (20%)	22 (59.5%)
	HPV+	35 (56.5%)	20 (80%)	15 (40.5%)
Anisokaryosis					<0.001
	Mild	28 (45.2%)	20 (80%)	8 (21.6%)
	Moderate	19 (30.6%)	5 (20%)	14 (37.8%)
	Marked	15 (24.2%)	0 (0%)	15 (40.5%)
CENP-A H-score					0.003
	Median (IQR)	1.6 (1.2–2.7)	1.8 (1.6–2.7)	1.5 (0.7–1.8)
Local Disease Control at 2 years					<0.001
	Yes	38 (61.3%)	24 (96%)	14 (37.8%)
	No	24 (38.7%)	1 (4%)	23 (62.2%)

NA: not available; NS: not significant.